Adverum Biotechnologies (ADVM) Competitors $2.94 -0.09 (-2.81%) As of 01:03 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. GALT, TVRD, NGNE, LFCR, MREO, ACB, RNAC, CADL, MNPR, and NMRAShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Galectin Therapeutics (GALT), Tvardi Therapeutics (TVRD), Neurogene (NGNE), Lifecore Biomedical (LFCR), Mereo BioPharma Group (MREO), Aurora Cannabis (ACB), Cartesian Therapeutics (RNAC), Candel Therapeutics (CADL), Monopar Therapeutics (MNPR), and Neumora Therapeutics (NMRA). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors Galectin Therapeutics Tvardi Therapeutics Neurogene Lifecore Biomedical Mereo BioPharma Group Aurora Cannabis Cartesian Therapeutics Candel Therapeutics Monopar Therapeutics Neumora Therapeutics Adverum Biotechnologies (NASDAQ:ADVM) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations. Which has stronger valuation and earnings, ADVM or GALT? Galectin Therapeutics has lower revenue, but higher earnings than Adverum Biotechnologies. Galectin Therapeutics is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdverum Biotechnologies$1M61.58-$130.93M-$7.85-0.37Galectin TherapeuticsN/AN/A-$47.05M-$0.64-7.20 Which has more volatility & risk, ADVM or GALT? Adverum Biotechnologies has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Do insiders and institutionals hold more shares of ADVM or GALT? 48.2% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 11.7% of Galectin Therapeutics shares are held by institutional investors. 6.0% of Adverum Biotechnologies shares are held by insiders. Comparatively, 50.1% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer ADVM or GALT? In the previous week, Galectin Therapeutics had 4 more articles in the media than Adverum Biotechnologies. MarketBeat recorded 6 mentions for Galectin Therapeutics and 2 mentions for Adverum Biotechnologies. Adverum Biotechnologies' average media sentiment score of 1.79 beat Galectin Therapeutics' score of 0.62 indicating that Adverum Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adverum Biotechnologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Galectin Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ADVM or GALT? Adverum Biotechnologies currently has a consensus price target of $19.75, suggesting a potential upside of 572.91%. Galectin Therapeutics has a consensus price target of $6.00, suggesting a potential upside of 30.29%. Given Adverum Biotechnologies' higher possible upside, equities analysts plainly believe Adverum Biotechnologies is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ADVM or GALT more profitable? Galectin Therapeutics' return on equity of 0.00% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adverum BiotechnologiesN/A -297.29% -101.40% Galectin Therapeutics N/A N/A -225.32% SummaryAdverum Biotechnologies beats Galectin Therapeutics on 8 of the 14 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.53M$3.14B$5.75B$10.25BDividend YieldN/A2.36%5.88%4.63%P/E Ratio-0.3721.3076.9526.52Price / Sales61.58458.41527.94122.10Price / CashN/A45.4037.1760.46Price / Book0.869.6713.956.32Net Income-$130.93M-$53.02M$3.29B$270.92M7 Day Performance-11.33%1.41%1.28%2.49%1 Month Performance2.62%5.02%5.00%6.95%1 Year Performance-59.79%9.45%84.58%27.73% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies4.0659 of 5 stars$2.94-2.8%$19.75+572.9%-58.1%$61.53M$1M-0.37190Positive NewsGALTGalectin Therapeutics1.8343 of 5 stars$4.67+1.5%$6.00+28.5%+62.1%$294.68MN/A-7.309News CoverageTVRDTvardi Therapeutics2.9228 of 5 stars$29.66-4.7%$64.25+116.6%N/A$291.73M$7.14M0.0080News CoveragePositive NewsGap UpNGNENeurogene1.7247 of 5 stars$19.45-2.5%$46.17+137.4%-59.2%$284.73M$930K-4.5190Positive NewsLFCRLifecore Biomedical0.7598 of 5 stars$7.29-3.2%$8.00+9.7%+54.4%$281.68M$128.87M-5.56690MREOMereo BioPharma Group2.3905 of 5 stars$1.79+1.1%$7.40+313.4%-60.9%$281.43M$10M-25.5740Positive NewsACBAurora Cannabis0.5424 of 5 stars$4.84-1.4%N/A-15.3%$277.19M$246.72M-25.471,130Positive NewsRNACCartesian Therapeutics2.3533 of 5 stars$10.19-4.2%$40.00+292.5%-40.0%$276.66M$38.91M-0.1964Positive NewsCADLCandel Therapeutics2.4937 of 5 stars$5.10+2.0%$20.00+292.2%-33.4%$274.48M$120K-7.3960Positive NewsMNPRMonopar Therapeutics2.5011 of 5 stars$41.48-6.2%$69.57+67.7%+1,260.4%$272.77MN/A-12.4610News CoverageAnalyst ForecastGap UpNMRANeumora Therapeutics2.83 of 5 stars$1.66-1.2%$7.14+330.3%-87.4%$272.07MN/A-1.06108News CoverageAnalyst Downgrade Related Companies and Tools Related Companies GALT Alternatives TVRD Alternatives NGNE Alternatives LFCR Alternatives MREO Alternatives ACB Alternatives RNAC Alternatives CADL Alternatives MNPR Alternatives NMRA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADVM Stock Alerts